aXichem (AXIC) Q4 2024 earnings summary

Executive summary

• Net sales for 2024 reached SEK 8,570 thousand, a significant increase from SEK 1,809 thousand in 2023, marking the company's strongest sales year to date.

• Operating profit for the year was SEK -15,827 thousand, improving from SEK -17,318 thousand in the previous year.

• Profit after tax improved to SEK -17,815 thousand from SEK -20,814 thousand year-over-year.

• Major product launches and new orders in both dietary supplements (aXivite) and animal feed (aXiphen) segments contributed to growth.

Financial highlights

• Net sales increased by 374% year-over-year to SEK 8,570 thousand.

• Operating loss narrowed to SEK -15,827 thousand from SEK -17,318 thousand year-over-year.

• Cash and cash equivalents at year-end were SEK 14,359 thousand, up from SEK 4,309 thousand.

• Equity ratio improved to 94% from 79% year-over-year.

• Earnings per share improved to SEK -0.46 from SEK -1.03 year-over-year.

Outlook and guidance

• Commercialization of phenylcapsaicin under aXiphen and aXivite brands continues, with production and logistics capacity in place.

• Market establishment in Brazil and the EU prioritized for animal feed, with ongoing regulatory processes in the EU and US.

• No financial forecasts or forecast-like targets will be published going forward.